Chemotherapy is presently the front-line standard of care for advanced NSCLC and the combination of PARP inhibition, and anti-PDL1 immune checkpoint inhibition is being explored in a switch maintenance study design. Here, CD274 is linked to non-small cell lung carcinoma.